Document:

Exhibit 10.2

 

CONSULTING AGREEMENT

 

THIS AGREEMENT made as of the 12th day of December,
2022.

 

BETWEEN:

 

INMED PHARMACEUTICALS INC., a corporation
registered in the Province of British Columbia and having its principal place of business at 310-815 W. Hastings St., Vancouver, BC, V6C
1B4, Canada,

 

(the “Company”)

 

		AND:	BRIO FINANCIAL GROUP, a corporation incorporated under the laws of USA, having an office address
at 100 Somerset Corporate Blvd., 2nd Floor, Bridgewater, New Jersey 08807, USA,

 

(“Brio”)

 

		AND:	JONATHAN TEGGE, a financial professional associated with Brio, with an address of 100 Somerset
Corporate Blvd., 2nd Floor, Bridgewater, New Jersey 08807, USA.

 

(the “Consultant”)

 

(with Company, Brio and Consultant, jointly, the “Parties”).

 

WHEREAS:

 

		A.	The Company is a global leader in the research, development,
manufacturing and commercialization of rare cannabinoids and wishes to retain the services of the Consultant;

 

		B.	The Consultant has relevant experience as a senior financial
leader and Interim Chief Financial Officer; and

 

		C.	The Company wishes to retain the Consultant and the Consultant
wishes to be retained to provide consulting advice to the Company with respect to the advancement of its Business and other related matters
on the terms and conditions set out in this Agreement.

 

     

     

    

 

NOW THEREFORE THIS AGREEMENT
WITNESSES that for and in consideration of the premises and mutual covenants and agreements hereinafter contained, the Company and
the Consultant agree as follows:

 

Section 1 - Interpretation

 

		1.1	In and for the purposes of this Agreement, unless there is something in the subject matter or context
inconsistent therewith, each of the following words, phrases and expressions will have the meanings ascribed to them below:

 

		(a)	“Business” means all activities of the Company and its affiliates (as affiliate is
defined in the Business Corporations Act (British Columbia));

 

		(b)	“Company” includes any related or affiliated entity;

 

		(c)	“Confidential Information” includes, but is not limited to, all information related
to processes, formulae, research, development, financial and business information, trade secrets or other proprietary information in whatever
form, concerning the past, present and planned future products, services, operations and marketing techniques and procedures of the Company,
and further includes any information related to the past, present and prospective customers, suppliers, clients, distributors and employees
of the Company, but does not include information which is in the public domain, without any fault or responsibility on the part of the
Consultant.

 

		(d)	“Effective Date” means the date this Agreement is fully executed.

 

		(e)	“Material” includes all documentation, work-in-progress, reports and other materials
the Consultant produces in the course of providing the Services;

 

		(f)	“Services” includes various financial related matters, including being named as the
Interim Chief Financial Officer of the Company, as agreed to between the parties from time to time and as further detailed in the financial
services agreement between the Parties;

 

		(g)	“Term” means the time period from the date of this Agreement until this Agreement is
terminated in accordance with Section 6.

 

		1.2	For the purposes of this Agreement, the singular of any term includes the plural, and vice versa, the
use of any term is generally applicable to either gender and, where applicable, to a corporation, the word “or” is not exclusive
and the word “including” is not limiting whether or not non-limiting language (such as “without limitation” or
“but not limited to” or words of similar import) is used with reference thereto.

 

Section 2- Engagement

 

		2.1	The Company retains and engages the Consultant to provide the Services in accordance with the terms and
conditions of this Agreement and the Consultant agrees to accept such retainer.

 

		2.2	The engagement of the Consultant under this Agreement will continue until such time as the Agreement is
terminated in accordance with 6.

 

Section 3 - Services

 

		3.1	During the Term, the Consultant will be available to provide the Services to the Company on a part-time
basis, compatible with the Consultant’s schedule.

 

		3.2	The Consultant will perform the Services in a competent and professional manner and fully in accordance
with all policies of the Company and all applicable laws and regulations.

 

		3.3	The Consultant will not subcontract out any portion of the Services and will perform the Services personally.

 

    2

     

    

 

Section 4- Compensation

 

		4.1	Service Fees. Under a separate agreement between the Company and Brio, financial terms have been
set by which the Company pays Brio a monthly retainer (and, possibly, other agreed to fees), from which Brio will compensate the Consultant
directly. The Consultant acknowledges and agrees that Brio shall be solely responsible for all compensation that may be owed to the Consultant
under this Agreement, and that the Consultant shall not look to the Company nor seek to hold the Company responsible for payment of any
compensation that may be owing or owed to the Consultant in connection with the Consultant’s performance of Services under the engagement
between the Parties. Brio will indemnify and hold harmless the Company from any and all claims, demands, complaints, actions, damages,
costs and expenses, including legal expenses on a solicitor-and-own-client basis, for any claims made by the Consultant for compensation
from the Company under this Agreement in relation to the performance of the Consultant’s obligations under this Agreement or the
engagement between the Parties, except as expressly contemplated herein.

 

		4.2	Expenses. Subject to the following provisions:

 

		(a)	Compliance with Company Policies. Subject to compliance by the Consultant with the Company’s
expense and travel policies as may be in effect from time to time; and

 

		(b)	Expense Reports. Provided that the Consultant provides the Company with written expense accounts
including receipts;

 

the Company shall
reimburse the Consultant for all reasonable expenses incurred in the performance of this Agreement.

 

		4.3	Options. The Company agrees to issue to options to Brio and Consultant upon execution of this Agreement
as follows:

 

		(a)	Brio shall receive an option to purchase 1,400 common shares of Company at a purchase price not less than
fair market value on the date of issuance (date to be determined in conjunction with the annual options pricing/issuance for employees
and Directors; currently anticipated in December 2022) (the “Brio Options”). The Brio Options will vest 100% upon issuance
and will expire 5 years from issuance date, or otherwise as per the Company Stock Option Plan upon the termination of the agreement between
the Company and Brio; and

 

		(b)	The Consultant shall receive an option to purchase 1,400 common shares of Company at a purchase price
not less than fair market value on the date of issuance (date to be determined in conjunction with the annual options pricing/issuance
for employees and Directors; currently anticipated in December 2022) (the “Consultant Options”). The Consultant Options
will vest 1/12 per month over a 12-month period from issuance and will expire 5 years from issuance date, or otherwise as per the Company
Stock Option Plan upon the termination of the agreement between the Company and Consultant.

 

    3

     

    

 

Section 5– Debarment

 

		5.1	The Consultant certifies that he is not under investigation by the United States Food and Drug Administration
(the “FDA”) for debarment action and has not been debarred under and that he will not use in any capacity the services
of any person or entity that is under investigation for debarment action under the Generic Drug Enforcement Act of 1992 (21 U.S.C. 301
et seq.) or has been so debarred, or who is otherwise restricted or disqualified from performing services relating to clinical trials,
to perform any Services under this Agreement. If, during the course of this Agreement, the Consultant becomes aware that the Consultant
is under investigation by the FDA or any health regulatory authority for debarment action or is debarred, or otherwise restricted or disqualified;

 

		(a)	the Consultant shall promptly inform the Company of such event and, upon the Company’s request,
will assist the Company in conducting an inquiry or audit regarding the Services performed by the Consultant for the Company; and

 

		(b)	the Company may in its sole discretion elect to terminate this Agreement with immediate effect for material
breach, without any prior notice or payment in lieu of notice to the Consultant.

 

Section 6 –
Termination

 

		6.1	The following terms and conditions apply to a termination of the engagement of the Consultant pursuant
to this Agreement:

 

		(a)	either party may terminate this Agreement for convenience at any time upon seven (7) days’ written
notice to the other party; or

 

		(b)	either party may terminate this Agreement without notice or any payment in lieu of notice in the event
of a material breach by the other party of any term of this Agreement.

 

Section 7 –
Confidentiality, Ownership of Material and Assignment of Intellectual Property Rights

 

		7.1	The Consultant is required to review and sign a Confidentiality and Assignment of Inventions Agreement
between the Company and the Consultant attached to this Agreement and dated as of the Effective Date.

 

Section 8- Non-Exclusive
Services

 

		8.1	The Company acknowledges and agrees that the Consultant is providing Services to the Company during the
Term of this Agreement on a non-exclusive basis. The Company acknowledges that the Consultant may provide services to other companies
and that some of these engagements may be in conflict with the business of the Company.

 

    4

     

    

 

Section 9 –
Relationship between the Parties

 

		9.1	This Agreement does not constitute or create an employment, employment-like, agency, partnership or joint
venture relationship between the Consultant and the Company.

 

		9.2	The Consultant agrees and acknowledges that the Consultant does not have the authority to enter into contracts
on behalf of the Company, nor to legally bind the Company in any way, except with the prior written consent of the Company.

 

		9.3	In the performance of the engagement contemplated by this Agreement, the Consultant acknowledges and agrees
they are an independent contractor. The Consultant agrees and acknowledges that they are not a dependent contractor, as that term is understood
under the common law. The Consultant represents that they understand the distinction, or has been afforded the opportunity to inform themself
of the distinction by engaging legal counsel, between an independent contractor on one hand and an employee or dependent contractor on
the other hand. In understanding this difference, the Consultant agrees that they are not entitled to any additional notice or termination,
pay in lieu of notice of termination, or a combination of either beyond what is expressly provided in this Agreement.

 

		9.4	The Consultant and Brio will be wholly responsible for all taxes and other fees levied on the fees and
services under this Agreement. Without limitation, the Consultant and Brio will make, and will indemnify the Company for, all statutory
contributions and remittances, including, without limitations, federal and provincial sales tax, any taxes pursuant to the Income Tax
Act, employment insurance, pension, workers’ compensation, other similar levies, and all fines and penalties levied for failure
to make payment.

 

Section 10- General
Provisions

 

		10.1	Severability. Each provision of this Agreement constitutes a separate and distinct obligation and
if any provision of this Agreement is determined to be void or unenforceable, in whole or in part, it will be deemed not to affect or
impair the validity of any other obligation or provision.

 

		10.2	Entire Agreement. The terms and conditions contained within this Agreement (including the Appendices),
in combination with the Engagement Letter by and between the Company and Brio, constitute the entire agreement between the Parties hereto.

 

		10.3	Succession. This Agreement will enure to the benefit of and be binding upon each of the Company
and the Consultant and their respective successors and assigns, and may not be assigned or transferred by either party except with the
prior written consent of the other party.

 

		10.4	Notices. Any notices to be given hereunder by either party to the other party may be effected in
writing, either by personal delivery, by mail if sent certified, postage prepaid, with return receipt requested or by email upon acknowledgment
of receipt. Mailed notices will be addressed to the parties at the address set out on the first page of this Agreement, or as otherwise
specified from time to time. Mailed notice will be effective upon delivery. If emailed to the Consultant, at jtegge@briofinancial.com;
if mailed to Brio, at dbrioned@briofinancial.com; and if emailed to the Company at eadams@inmedpharma.com.

  

		10.5	Amendments and Waivers. No amendment to this Agreement will be valid or binding unless set forth
in writing and duly executed by all of the parties hereto. No waiver of any breach of any provision of this Agreement will be effective
or binding unless made in writing and signed by the party purporting to give the same and, unless otherwise provided in the written waiver,
will be limited to the specific breach waived.

 

		10.6	Survival. Notwithstanding the expiration or early termination of this Agreement, Sections 1.1,
1.2, 5, 6, 7, 9.3, 9.4, this Section 10 and Appendix A shall survive any termination of this Agreement.

 

		10.7	Governing Law. This Agreement will be governed by and construed, enforced and interpreted exclusively
in accordance with the laws of the Province of British Columbia and the applicable laws of Canada therein.

 

		10.8	Independent Legal Advice. The Consultant specifically confirms that the Consultant has been provided
with the opportunity to retain independent legal advice prior to entering into this Agreement.

 

(The
Remainder of the Page has been Intentionally Left Blank.)

 

    5

     

    

 

IN WITNESS WHEREOF the parties have executed this Agreement
as of the date first above written.

 

INMED PHARMACEUTICALS, INC.

 

	 	 
	Eric A. Adams, 	 
	Chief Executive Officer	 

 

	Date:	 	 

 

BRIO FINANCIAL GROUP

 

	 	 
	David Briones,	 

 

	Date:	 	 

 

	 	 
	Jonathan Tegge	 
	Consultant	 

 

	Date:	 	 

 

    6

     

    

 

APPENDIX A

 

CONFIDENTIALITY

AND ASSIGNMENT OF INVENTIONS AGREEMENT

 

THIS AGREEMENT (this “Agreement”) dated for reference
the 12th day of December, 2022 (the “Effective Date”).

 

BETWEEN:

INMED PHARMACEUTICALS INC., a company
incorporated under the laws of British Columbia (the “Company”), with offices at Suite 310, 815 W. Hastings Street,
Vancouver, B.C. V6C 1B4, Canada,

 

AND: 

JONATHAN TEGGE, a financial
professional associated with Brio, with an address of 100 Somerset Corporate Blvd., 2nd Floor, Bridgewater, New Jersey 08807, USA (the
“Consultant”)

 

WHEREAS:

 

A.  The
Company is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids;

 

B.  In
connection with the engagement of Brio Financial Group, and the secondment of the Consultant to the Company, the parties desire to establish
the terms and conditions under which the Consultant will (i) receive from and disclose to the Company proprietary and confidential information;
(ii) agree to keep the information confidential, to protect it from disclosure and to use it only in accordance with the terms of this
Agreement; and (iii) assign to the Company all rights, including any ownership interest which may arise in all inventions and intellectual
property developed or disclosed by the Consultant over the course of the Consultant’s work with the Company, as set out in this
Agreement.

 

NOW THEREFORE THIS AGREEMENT WITNESSES that in consideration of the
engagement of the Consultant by the Company and the payment by the Company to the Consultant of the sum of $1.00 and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

		1.	INTERPRETATION

 

		1.1	Definitions.
                                            In
                                            this Agreement:

 

		(a)	“Affiliate” means, in respect of the Company, a company or other entity which directly
or indirectly controls, is controlled by, or is under common control with, the Company. For the purposes of this definition, “control”
means direct or indirect beneficial ownership of a greater than 50% interest in the income of such company or entity or such other relationship
as, in fact, constitutes actual control.

 

    7

     

    

 

		(b)	“Business” or “Business of the Company” means: researching, developing,
commercializing, producing and marketing novel, cannabinoid-based therapies and other commercial products; or any other area in which
the Company has an active research and development program on the date the Consultant’s engagement with the Company terminates and
in connection with which the Consultant directly provided service or had direct supervisory responsibilities.

 

		(c)	“Confidential Information” shall mean all information, knowledge, or data, whether
in written, oral, electronic or other form, relating to the Business of the Company, whether or not conceived, originated, discovered
or developed in whole or in part by the Consultant, that is not generally known to the public or to other persons who are not bound by
obligations of confidentiality and:

 

		(i)	from which the Company or its Affiliates derive economic value, actual
or potential, from the information not being generally known; or

 

		(ii)	in respect of which the Company or its Affiliates otherwise have a legitimate
interest in maintaining secrecy;

 

and which, without limiting the generality of the foregoing,
shall include:

 

		(iii)	all proprietary information licensed to, acquired, used or developed
by the Company and its Affiliates in its research and development activities (including but not restricted to the research and development
of cannabinoid drugs and delivery technology), other scientific strategies and concepts, designs, know-how, information, material, formulas,
processes, research data and proprietary rights in the nature of copyrights, patents, trademarks, licenses and industrial designs;

 

		(iv)	all information relating to the Business of the Company, and to all
other aspects of the structure, personnel and operations of the Company and its Affiliates, including financial, clinical, regulatory,
marketing, advertising and commercial information and strategies, customer lists, compilations, agreements and contractual records and
correspondence; programs, devices, concepts, inventions, designs, methods, processes, data, know-how, unique combinations of separate
items that is not generally known and items provided or disclosed to the Company or its Affiliates by third parties subject to restrictions
on use or disclosure;

 

		(v)	all know-how relating to the Business of the Company, including all
biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, clinical, safety, manufacturing and quality
control data and information, and all applications, registrations, licences, authorizations, approvals and correspondence submitted to
regulatory authorities;

 

    8

     

    

 

		(vi)	all information relating to the businesses of competitors of the Company
or its Affiliates, including information relating to competitors’ research and development, intellectual property, operations, financial,
clinical, regulatory, marketing, advertising and commercial strategies, that is not generally known; 

 

		(vii)	all information provided to the Company or its Affiliates by their agents,
consultants, lawyers, contractors, licensors or licensees and relating to the Business of the Company; and

 

		(viii)	all information relating to the Consultant’s compensation and
benefits except that the Consultant shall be entitled to disclose such information to the Consultant’s bankers, advisors, agents,
consultants and other third parties who have a duty of confidence to him and who have a need to know such information in order to provide
advice, products or services to him.

 

		(ix)	All Work Product shall be deemed to be the Company’s Confidential
Information.

 

		(d)	“Intellectual Property” is
used in its broadest sense and means and includes any statutory, common law, equitable, contractual or proprietary rights or interests,
recognized currently or in future, in and to any Inventions, including, without limitation, rights and interests in and to the following:

 

		(i)	knowledge, know-how and its embodiments, including trade secret information;

 

		(ii)	patents in inventions, and all applications therefor; 

 

		(iii)	copyrights in artistic, literary, dramatic, musical, and neighbouring
works, copyrightable works of authorship including technical descriptions for products, user guides, illustrations, advertising materials,
computer programs, source code and object code, and all applications therefor; 

 

		(iv)	trademarks, service marks, tradenames, business names and domain names
and all applications therefor; 

 

		(v)	industrial designs and all other industrial or intellectual property
and all applications therefor; and

 

		(vi)	all goodwill connected with the foregoing.

 

    9

     

    

 

		(e)	“Inventions” shall mean any and all inventions, discoveries, developments, enhancements,
improvements, concepts, formulas, designs, processes, ideas, writings and other works, whether or not reduced to practice, and whether
or not protectable under patent, copyright, trade secret or similar laws.

 

		(f)	“Work Product” shall mean
any and all Inventions and possible Inventions relating to the Business of the Company and which the Consultant may make or conceive,
alone or jointly with others, during the Consultant’s involvement in any capacity with the Company, whether during or outside the
Consultant’s regular working hours, except those Inventions made or conceived by the Consultant entirely on the Consultant’s
own time that do not relate to the Business of the Company and do not derive from any equipment, supplies, facilities, Confidential Information
or other information, gained, directly or indirectly, from or through the Consultant’s involvement in any capacity with the Company.

 

		2.	CONFIDENTIALITY

 

		2.1	Prior
                                            Business Confidential Information. The
                                            Consultant represents and warrants to the Company that the Consultant has not brought or
                                            used, and the Consultant covenants and agrees that the Consultant will not use or bring to
                                            the Company any confidential information of any kind whatsoever of any prior party (the “Prior
                                            Business”) with whom the Consultant was previously
                                            involved, whether such involvement was as an employee, director or officer of that Prior
                                            Business, an investor in that Prior Business, a partner in that Prior Business, a consultant
                                            to that Prior Business or other relationship to that Prior Business (the “Prior
                                            Involvement”). The Company and the Consultant acknowledge
                                            and agree that the Company is not engaging the Consultant to obtain confidential information
                                            relating to any Prior Involvement and the Consultant acknowledges that the Company has advised
                                            the Consultant to comply with any and all legal obligations the Consultant may have to such
                                            Prior Business. The Consultant covenants and agrees to hold the Company harmless from any
                                            and all claims and damages of any kind whatsoever that the Company may suffer as a result
                                            of any breach by the Consultant of the Consultant’s obligations to such Prior Business
                                            in that regard.

 

		2.2	Basic
                                            Obligation of Confidentiality. The
                                            Consultant hereby acknowledges and agrees that in the course of the Consultant’s involvement
                                            with the Company, the Company may disclose to the Consultant may otherwise have access or
                                            be exposed to Confidential Information. The Company hereby agrees to provide such access
                                            to the Consultant and the Consultant hereby agrees to receive and hold all Confidential Information
                                            on the terms and conditions set out in this Agreement. Except as otherwise set out in this
                                            Agreement, the Consultant will keep strictly confidential all Confidential Information and
                                            all other information belonging to the Company that the Consultant acquires, observes or
                                            is informed of, directly or indirectly, in connection with the Consultant’s involvement,
                                            in any capacity, with the Company both during and after the term of the Consultant’s
                                            engagement in any capacity with the Company.

 

    10

     

    

 

		2.3	Non-disclosure.
                                            Except with
                                            the prior written consent of the Company, the Consultant will not at any time, either during
                                            or after the Consultant involvement in any capacity with the Company;

 

		(a)	use or copy any Confidential Information or recollections thereof for any purpose other than the performance
of the Consultant’s duties for the benefit of the Company and its Affiliates;

 

		(b)	publish or disclose any Confidential Information or recollections thereof to any person other than to
employees of the Company and its Affiliates who have a need to know such Confidential Information in the performance of their duties for
the Company or its Affiliates; or

 

		(c)	permit or cause any Confidential Information to be used, copied, published, disclosed, translated or adapted
except as otherwise expressly permitted by this Agreement;

 

		2.4	Taking
                                            Precautions. The
                                            Consultant will take all reasonable precautions necessary or prudent to prevent material
                                            in the Consultant’s possession or control that contains or refers to Confidential Information
                                            from being discovered, used or copied by third parties.

 

		2.5	The
                                            Company’s Ownership of Confidential Information.
                                            As between
                                            the Consultant and the Company, the Company shall own all right, title and interest in and
                                            to the Confidential Information, whether or not created or developed by the Consultant.

 

		2.6	Control
                                            of Confidential Information and Return of Information.
                                            All physical
                                            materials produced or prepared by the Consultant containing Confidential Information, including,
                                            without limitation, records, devices, computer files, data, notes, reports, proposals, lists,
                                            correspondence, specifications, drawings, plans, materials, accounts, reports, financial
                                            statements, estimates and all other materials prepared in the course of the Consultant’s
                                            responsibilities to or for the benefit of the Company or its Affiliates, together with all
                                            copies thereof (in whatever medium recorded), shall belong to the Company, and the Consultant
                                            will promptly turn over to the Company’s possession every original and copy of any
                                            and all such items in the Consultant’s possession or control upon request by the Company
                                            except the Consultant may retain one copy of such Confidential Information in its legal archives
                                            for the sole purpose of determining and meeting its obligations under this Agreement.. If
                                            the material is such that it cannot reasonably be delivered, upon request from the Company,
                                            the Consultant will provide reasonable evidence that such materials have been destroyed,
                                            purged or erased.

 

    11

     

    

 

		2.7	Purpose
                                            of Use. The
                                            Consultant agrees that the Consultant will use Confidential Information only for purposes
                                            authorized or directed by the Company.

 

		2.8	Exemptions.
                                            The
                                            obligations of confidentiality set out in this Article 2 will not apply to any of the following:

 

		(a)	information that is already known to the Consultant, though not due to a prior disclosure by the Company
or its Affiliates or by a person who obtained knowledge of the information, directly or indirectly, from the Company or its Affiliates;

 

		(b)	information disclosed to the Consultant by another person who is not obliged to maintain the confidentiality
of that information and who did not obtain knowledge of the information, directly or indirectly, from the Company or its Affiliates;

 

		(c)	information that is developed by the Consultant independently of Confidential Information received from
the Company or its Affiliates and such independent development can be documented by the Consultant;

 

		(d)	other particular information or material which the Company expressly exempts by written instrument signed
by the Company;

 

		(e)	information or material that is in the public domain through no fault of the Consultant; and

 

		(f)	information required by operation of law, court order or government agency to be disclosed, provided that:

 

		(i)	in the event that the Consultant is required to disclose such information
or material, upon becoming aware of the obligation to disclose, the Consultant will provide to the Company prompt written notice so that
the Company may seek a protective order or other appropriate remedy and/or waive compliance with the provisions of this Agreement;

 

		(ii)	if the Company agrees that the disclosure is required by law, it will
give the Consultant written authorization to disclose the information for the required purposes only;

 

		(iii)	if the Company does not agree that the disclosure is required by law,
this Agreement will continue to apply, except to the extent that a Court of competent jurisdiction orders otherwise; and

 

		(iv)	if a protective order or other remedy is not obtained or if compliance
with this Agreement is waived, the Consultant will furnish only that portion of the Confidential Information that is legally required
and will exercise all reasonable efforts to obtain confidential treatment of such Confidential Information.

 

    12

     

    

 

		3.	ASSIGNMENT OF INTELLECTUAL PROPERTY RIGHTS

 

		3.1	Notice
                                            of Invention. The
                                            Consultant agrees to promptly and fully inform the Company of all Work Product, whether or
                                            not patentable, throughout the course of the Consultant’s involvement, in any capacity,
                                            with the Company and from which there is a reasonable basis to believe that Intellectual
                                            Property may be derived therefrom, whether or not developed before or after execution of
                                            this Agreement. On the Consultant’s ceasing to be engaged by the Company for any reason
                                            whatsoever, the Consultant will immediately deliver up to the Company all Work Product. 

 

		3.2	Assignment
                                            of Rights. Subject
                                            only to the exceptions set out in Attachment 1 attached to this Agreement, the Consultant
                                            will assign, and does hereby assign, to the Company or, at the option of the Company and
                                            upon notice from the Company, to the Company’s designee, all of the Consultant’s
                                            right, title and interest in and to all Work Product, including all Intellectual Property
                                            rights therein. To the extent that the Consultant retains or acquires legal title to any
                                            such Intellectual Property rights and interests, the Consultant hereby declares and confirms
                                            that such legal title is and will be held by him only as trustee and agent for the Company
                                            or the Company’s designee. The Consultant agrees that the Company’s rights hereunder
                                            shall attach to all Intellectual Property rights in the Consultant’s Work Product,
                                            notwithstanding that it may be perfected or reduced to specific form after the Consultant
                                            has terminated the Consultant’s relationship with the Company. The Consultant further
                                            agrees that the Company’s rights hereunder are worldwide rights and are not limited
                                            to Canada, but shall extend to every country of the world.

 

		3.3	Moral
                                            Rights. Without
                                            limiting the foregoing, the Consultant hereby irrevocably waives any and all moral rights
                                            arising under the Copyright Act (Canada), as amended, or any successor legislation of similar
                                            force and effect or similar legislation in other applicable jurisdictions or at common law
                                            that the Consultant may have with respect to all Work Product, and agrees never to assert
                                            any moral rights which the Consultant may have in the Work Product, including, without limitation,
                                            the right to the integrity of the Work Product, the right to be associated with the Work
                                            Product, the right to restrain or claim damages for any distortion, mutilation or other modification
                                            or enhancement of the Work Product and the right to restrain the use or reproduction of the
                                            Work Product in any context and in connection with any product, service, cause or institution,
                                            and the Consultant further confirms that the Company may use or alter any Work Product as
                                            the Company sees fits in its absolute discretion.

 

		3.4	Goodwill.
                                            The
                                            Consultant hereby agrees that all goodwill the Consultant has established or may establish
                                            with clients, customers, suppliers, principals, shareholders, investors, collaborators, strategic
                                            partners, licensees, contacts or prospects of the Company relating to the Business of the
                                            Company (or of its partners, subsidiaries or affiliates), both before and after the Effective
                                            Date, shall, as between the Consultant and the Company, be and remain the property of the
                                            Company exclusively, for the Company to use, alter, vary, adapt and exploit as the Company
                                            shall determine in its discretion.

 

    13

     

    

 

		3.5	Assistance.
                                            The
                                            Consultant hereby agrees to reasonably assist the Company, at the Company’s request
                                            and expense, in:

 

		(a)	making patent applications for all Work Product, including instructions to lawyers and/or patent agents
as to the characteristics of the Work Product in sufficient detail to enable the preparation of a suitable patent specification, to execute
all formal documentation incidental to an application for letters patent and to execute assignment documents in favour of the Company
for such applications;

 

		(b)	making applications for all other forms of Intellectual Property registration relating to all Work Product;

 

		(c)	prosecuting and maintaining the patent applications and other Intellectual Property relating to all Work
Product; and

 

		(d)	registering, maintaining and enforcing the patents and other Intellectual Property registrations relating
to all Work Product.

 

If the Company is unable for any reason to secure the Consultant’s
signature with respect to any Work Product including, without limitation, to apply for or to pursue any application for any patents or
copyright registrations covering such Work Product, then the Consultant hereby irrevocably designates and appoints the Company and its
duly authorized officers and agents as the Consultant’s agent and attorney-in-fact, to act for and in the Consultant’s behalf
and stead to execute and file any papers, oaths and to do all other lawfully permitted acts with respect to such Work Product with the
same legal force and effect as if executed by him.

 

		3.6	Assistance
                                            with Proceedings. The
                                            Consultant further agrees to reasonably assist the Company, at the Company’s request
                                            and expense, in connection with any defence to an allegation of infringement of another person’s
                                            intellectual property rights, claim of invalidity of another person’s intellectual
                                            property rights, opposition to, or intervention regarding, an application for letters patent,
                                            copyright or trademark or other proceedings relating to Intellectual Property or applications
                                            for registration thereof.

 

		3.7	Commercialization.
                                            The
                                            Consultant understands that the decision whether or not to commercialize or market any Work
                                            Product is within the Company’s sole discretion and for the Company’s sole benefit
                                            and that no royalty or other consideration will be due or payable to him as a result of the
                                            Company’s efforts to commercialize or market any such Work Product.

 

		3.8	Prior Business Intellectual
Property. The Consultant represents and warrants to the Company that the Consultant has not brought or used, and the Consultant
covenants and agrees that the Consultant will not use or bring to the Company any Intellectual Property of any kind whatsoever of any
Prior Business with whom the Consultant had a Prior Involvement or any Intellectual Property directly owned by the Consultant. The Company
and the Consultant acknowledge and agree that the Company is not employing the Consultant to obtain Intellectual Property relating to
any Prior Involvement and the Consultant acknowledges that the Company has advised the Consultant to comply with any legal obligations
the Consultant may have to such Prior Business. The Consultant covenants and agrees to hold the Company harmless from any and all claims
and damages of any kind whatsoever that the Company may suffer as a result of any breach by the Consultant of the Consultant’s
obligations to such Prior Business in that regard.

 

		3.9	Prior Inventions.
In order to have them excluded from this Agreement, the Consultant has set forth on Attachment 1 attached to this Agreement a
complete list of all Inventions for which a patent application has not yet been filed that the Consultant has, alone or jointly with
others, conceived, developed or reduced to practice prior to the execution of this Agreement to which the Consultant has any right, title
or interest, and which relate to the Business of the Company. If such list is blank or no such list is attached, the Consultant represents
and warrants that there are no such prior Inventions.

 

    14

     

    

 

		4.	General

 

		4.1	Term.
                                            Subject to
                                            Section ‎4.10, the term of this Agreement is from
                                            the Effective Date and terminates on the date that the Consultant is no longer engaged by
                                            the Company in any capacity. 

 

		4.2	No
                                            Conflicting Obligations. The
                                            Consultant hereby represents and warrants that the Consultant has no agreements with or obligations
                                            to any other person with respect to the matters covered by this Agreement or concerning the
                                            Confidential Information that are in conflict with anything in this Agreement, except as
                                            disclosed in Attachment 1 attached to this Agreement.

 

		4.3	Publicity.
                                            The Consultant
                                            shall not, without the prior written consent of the Company, make or give any public announcements,
                                            press releases or statements to the public or the press regarding any Work Product or any
                                            Confidential Information.

 

		4.4	Further
                                            Assurances. The
                                            parties will execute and deliver to each other such further instruments and assurances and
                                            do such further acts as may be required to give effect to this Agreement.

 

		4.5	Notices.
                                            All notices
                                            and other communications that are required or permitted by this Agreement must be in writing
                                            and shall be hand delivered or sent by express delivery service or certified or registered
                                            mail, postage prepaid, or by facsimile transmission (with receipt confirmed in writing) to
                                            the parties at the addresses on page 1 of this Agreement. Any such notice shall be deemed
                                            to have been received on the earlier of the date actually received or the date five (5) days
                                            after the same was posted or sent. Either party may change its address or its facsimile number
                                            by giving the other party written notice, delivered in accordance with this section.

 

		4.6	Equitable
                                            Remedies. The
                                            Consultant understands and acknowledges that if the Consultant breaches any of the Consultant’s
                                            obligations under this Agreement, that breach may give rise to irreparable injury to the
                                            Company for which damages are an inadequate remedy. In the event of any such breach by the
                                            Consultant, in addition to all other remedies available to the Company at law or in equity,
                                            the Company will be entitled as a matter of right to apply to a court of competent jurisdiction
                                            for such relief by way of restraining order, injunction, decree or otherwise, as may be appropriate
                                            to ensure compliance with the provisions of this Agreement.

 

		4.7	Non-Waiver.
                                            Failure
                                            on the part of either party to complain of any act or failure to act of the other of them
                                            or to declare the other party in default of this Agreement, irrespective of how long such
                                            failure continues, will not constitute a waiver by such party of their rights hereunder or
                                            of the right to then or subsequently declare a default.

 

		4.8	Severability.
                                            In the event
                                            that any provision or part of this Agreement is determined to be void or unenforceable in
                                            whole or in part, the remaining provisions, or parts thereof, will be and remain in full
                                            force and effect.

 

		4.9	Entire
                                            Agreement. This
                                            Agreement constitutes the entire agreement between the parties with respect to the subject
                                            matter hereof and supersedes any and all agreements, understandings, warranties or representations
                                            of any kind, written or oral, express or implied, including any relating to the nature of
                                            the position or its duration, and each of the parties releases and forever discharges the
                                            other of and from all manner of actions, causes of action, claim or demands whatsoever under
                                            or in respect of any agreement.

 

		4.10	Survival. Notwithstanding
                                                                                                                                                                           the expiration or early termination of this Agreement, the provisions of Article ‎1,
                                                                                                                                                                           Article ‎2 (including the obligations of confidentiality and to return Confidential
                                                                                                                                                                           Information, which shall endure, with respect to each item of Confidential Information, for so long as those items fall within the
                                                                                                                                                                           definition of Confidential Information), Sections ‎3.2, 3.3, 3.4, 3.5, 3.6 and ‎3.8
                                                                                                                                                                           and Article ‎4 shall survive any expiration or early termination of this
                                                                                                                                                                           Agreement.

 

		4.11	Modification
                                            of Agreement. Any
                                            modification of this Agreement must be in writing and signed by both the Company and the
                                            Consultant or it will have no effect and will be void.

 

		4.12	Governing
                                            Law. This
                                            Agreement will be governed by and construed according to the laws of the Province of British
                                            Columbia, Canada, and the parties irrevocably attorn to the jurisdiction of the courts of
                                            British Columbia to resolve any disputes arising out of or in relation to this Agreement.

 

		4.13	Independent
                                            Legal Advice. The
                                            Consultant agrees that the Consultant has obtained, or has had an opportunity to obtain,
                                            independent legal advice in connection with this Agreement, and further acknowledge that
                                            the Consultant has read, understands, and agrees to be bound by all of the terms and conditions
                                            contained herein.

 

    15

     

    

 

IN WITNESS WHEREOF this Agreement has been executed by the parties
hereto as of the date and year first above written.

 

CONSULTANT

 

	By:	 	 	Date:	 
	 	Jonathan Tegge, Consultant 	 	 	 

 

INMED PHARMACEUTICALS INC.

 

	Per:	 	 	Date:	 
	 	Eric A. Adams	 	 	 
	 	Chief Executive Officer	 	 	 

 

 

16ttcm_ex101.htm

EXHIBIT 10.01
  
 CERTIFICATE OF DESIGNATIONS,
 PREFERENCES, RIGHTS AND LIMITATIONS OF
 SERIES G CONVERTIBLE PREFERRED STOCK
 OF
 TAUTACHROME INC.
  _____________________________
  
 Pursuant to Section 151 of the 
 Delaware General Corporation Law 
  
  _____________________________
  
 TAUTACHROME INC. a Delaware corporation (the “Corporation”), hereby certifies that the following resolution was duly approved and adopted by the Board of Directors of the Corporation (the “Board of Directors”) by a unanimous written consent of the Board of Directors dated November 16, 2022, in lieu of a meeting in accordance with Section 141(f) of the Delaware General Corporation Law, which resolution remains in full force and effect on the date hereof:
  
 RESOLVED, that pursuant to the authority expressly granted to and vested in the Board of Directors by the provisions of the Corporation’s Certificate of Incorporation, as amended (the “Certificate of Incorporation”) and in accordance with Section 151 of the of the Delaware General Corporation Law (the “DGCL”), there is hereby created, out of the remaining 99,669,400 authorized, unissued and undesignated shares of Preferred Stock, par value $0.0001 per share (the “Preferred Stock”) of the Corporation, a series of the Preferred Stock consisting of 10,000,000 shares, which series shall have the following powers, designations, preferences and relative, participating, optional or other rights, and the following qualifications, limitations and restrictions (in addition to any powers, designations, preferences and relative, participating, optional or other rights, and any qualifications, limitations and restrictions, set forth in the Certificate of Incorporation that are applicable to the Preferred Stock):
  
 1. Designation and Amount. A series of Preferred Stock designated as Series G Preferred Stock is hereby created out of the authorized and unissued shares of Preferred Stock (the “Series G Preferred Stock”), and the number of shares of Series G Preferred Stock constituting such series shall be 10,000,000. The voting powers, designations, preferences and relative, participating, optional or other special rights, and other qualifications, limitations or restrictions of the Series G Ptreferred Stock shall be as set forth in this resolution.
  
 2. Definitions. As used in this resolution, the following terms shall have the following meanings:
  
 “Bylaws” means the bylaws of the Corporation, as amended.
  
 “Business Day” means any day other than a Saturday, a Sunday, or any other day on which banking institutions in New York, New York are required or authorized to close by law or executive order.
  
  	 
	1
	

	 

 
  
 “Common Stock” means the common stock, par value $0.00001 per share, of the Corporation.
  
 “Person” means an individual, a partnership, a corporation, a limited liability company, an association, a joint stock company, a trust, a joint venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof.
  
 “Series G Holder” means a holder of record of one or more shares of Series G Preferred Stock, as reflected in the stock records of the Corporation, which may be treated by the Corporation as the absolute owner of such share or shares (as the case may be) for all purposes.
  
 3. Voting Rights. Except as hereinafter referred to or as otherwise required by law or in accordance with any voting rights that may from time to time be attached to any series of Preferred Stock, the holders of the Series G Preferred Stock shall be entitled, as such, to receive notice of, to attend and to vote at any meeting of the shareholders of the Corporation wherein each share of Series G Preferred stock shall have 100 votes.
  
 4. Conversion
  
 4.1 Optional Conversion.
  
 (a) Conversion Right. Subject to Section 4.2 hereof, at any time and from time to time, each Series G Holder shall have the right, but not the obligation, to convert all or any portion of the Series G Holder’s shares of Series G Preferred Stock into shares of Common Stock at the rate of 100 shares of Common Stock for each share of Series G Preferred Stock so converted (any such conversion, an “Optional Conversion”).
  
 (b) Notice of Optional Conversion. In order to effect an Optional Conversion, a Series G Holder shall (i) submit a written notice to the Corporation, duly executed by the Series G Holder and in the form attached hereto as Annex 1, stating that the Series G Holder irrevocably elects to convert the number of shares of Series G Preferred Stock specified in such notice effective on a date not less than 61 days from the date that such notice is submitted to the Corporation (such effective date, the “Effective Date”), and (ii) shall promptly surrender or cause to be surrendered to the Corporation an original certificate representing the shares of Series G Preferred Stock being converted, duly endorsed for transfer, or give notice to the Corporation that such certificates have been lost, stolen or destroyed and delivers the documentation required by Section 12 hereof to the Corporation (the “Optional Conversion Documents”).
  
 (c) Delivery of Common Stock. Upon receiving the Optional Conversion Documents, the Corporation shall, on the Effective Date, issue and deliver (i.e., deposit with a nationally recognized overnight courier service postage prepaid) to the Series G Holder or its nominee (i) that number of shares of Common Stock issuable upon conversion of such shares of Series G Preferred Stock under the Optional Conversion, and (ii) a certificate representing the number of shares of Series G Preferred Stock not being converted, if any.
  
  	 
	2
	

	 

 
  
 4.2 Automatic Conversion.
  
 (a) Conversion Events. Each outstanding share of Series G Preferred Stock shall automatically and immediately convert into 100 shares of Common Stock upon the earlier of (i) a Change of Control, and (ii) 5:00 p.m. Eastern Time on December 31, 2030 (the “Automatic Conversion”). In this resolution, “Change of Control” means the occurrence of any of the following events:
  
 (i) an acquisition after the date of this resolution by an individual or legal entity or “group” (as described in Rule 13d-5(b)(1) promulgated under the Exchange Act of 1934, as amended) of effective control (whether through legal or beneficial ownership of capital stock of the Corporation, by contract or otherwise) of in excess of 50% of the voting securities of the Corporation (other than by means of conversion of Series G Preferred Stock);
  
 (ii) the Corporation merges into or consolidates with any other Person, or any Person merges into or consolidates with the Corporation and, after giving effect to such transaction, the stockholders of the Corporation immediately prior to such transaction own less than 50% of the aggregate voting power of the Corporation or the successor entity of such transaction;
  
 (iii) the Corporation sells or transfers all or substantially all of its assets to another Person and the stockholders of the Corporation immediately prior to such transaction own less than 50% of the aggregate voting power of the acquiring entity immediately after the transaction; or
  
 (iv) the Corporation executes or is bound by an agreement providing for any of the events set forth in clauses (i) through (iii) above.
  
 (b) No Further Action. The Automatic Conversion will occur automatically and without any further action by the Series G Holders, whether or not original certificates representing such shares of Series G Preferred Stock are surrendered to the Corporation or its transfer agent.
  
 (c) Notice of Automatic Conversion. The Corporation shall promptly deliver notice of the occurrence of an Automatic Conversion to each Series G Holder (an “Automatic Conversion Notice”). Upon receiving an Automatic Conversion Notice, each Series G Holder shall (i) promptly surrender or cause to be surrendered to the Corporation all original certificates representing the Series G Holder’s Series G Preferred Stock, duly endorsed for transfer, or (ii) give notice to the Corporation that such certificates have been lost, stolen or destroyed and deliver the documentation required by Section 12 hereof to the Corporation (the documents required under items (i) or (ii) above, referred hereinafter as the “Automatic Conversion Documents”).
  
 (d) Delivery of Common Stock. Upon receiving the documents required under items (i) or (ii) in the paragraph above, the Corporation shall promptly issue and deliver (i.e., deposit with a nationally recognized overnight courier service postage prepaid) to the Series G Holder or its nominee that number of shares of Common Stock issuable upon conversion of such shares of Series G Preferred Stock under the Automatic Conversion.
  
  	 
	3
	

	 

 
  
 4.3 General Conversion Provisions.
  
 (a) Effect of Conversion on Series G Preferred Stock. All shares of Series G Preferred Stock that are converted pursuant to the Automatic Conversion or an Optional Conversion shall automatically, upon such conversion, be cancelled and retired and cease to exist, and shall not thereafter be reissued or sold and shall return to the status of authorized but unissued shares of Preferred Stock undesignated as to series. Upon the conversion of shares of Series G Preferred Stock pursuant to the Automatic Conversion or an Optional Conversion, all such shares shall thereupon cease to confer upon the Series G Holder thereof any rights (other than the right to receive the shares of Common Stock that such Series G Holder is entitled to receive pursuant to the Automatic Conversion or such Optional Conversion) of a Series G Holder of shares of Series G Preferred Stock, and the Person(s) in whose name the shares of Common Stock are to be issued upon the Automatic Conversion or such Optional Conversion shall be deemed to have become the Series G Holder(s) of record of such shares of Common Stock with all rights that a holder of such shares of Common Stock would have thereby.
  
 (b) Status of Common Stock. All shares of Common Stock delivered upon the Automatic Conversion or an Optional Conversion of shares of Series G Preferred Stock will, upon such conversion, be duly and validly authorized and issued, fully paid and non-assessable, free from all pre-emptive rights, free from all taxes, liens, security interests, charges and encumbrances (other than liens, security interests, charges or encumbrances created by or imposed upon the respective Series G Holder or taxes in respect of any transfer occurring contemporaneously therewith).
  
 (c) No Charge or Payment. The issuance of shares of Common Stock upon conversion of shares of Series G Preferred Stock pursuant to the Automatic Conversion or an Optional Conversion shall be made without payment of additional consideration by, or other charge, cost or tax to, the respective Series G Holder; except that, the Corporation shall not be required to pay any tax or other governmental charge that may be payable with respect to the issuance or delivery of any shares of Common Stock in the name of any Person other than the Series G Holder of the converted shares of Series G Preferred Stock, and no such delivery shall be made unless and until the Person requesting such issuance has paid to the Corporation the amount of any such tax or charge, or has established to the satisfaction of the Corporation that such tax or charge has been paid or that no such tax or charge is due.
  
 (d) Reservation of Common Stock. The Corporation shall at all times reserve and keep available out of its authorized but unissued shares of Common Stock, solely for the purpose of issuance upon conversion of Series G Preferred Stock, such number of shares of Common Stock as would be issuable upon the conversion of all outstanding shares of Series G Preferred Stock. The Corporation shall take all such actions as may be necessary to assure that all such shares of Common Stock may be so issued without violation of any applicable law or governmental regulation applicable to the Corporation or any requirements of any securities exchange upon which shares of Common Stock may be listed (except for official notice of issuance which shall be immediately delivered by the Corporation upon each such issuance). The Corporation shall not take any action that would cause the number of authorized but unissued shares of Common Stock to be less than the number of such shares required to be reserved hereunder for issuance upon conversion of the outstanding shares of Series G Preferred Stock.
  
 (e) No Fractional shares of Common Stock. No fractional shares of Common Stock shall be issued upon the Automatic Conversion or an Optional Conversion. In lieu of delivering a fractional share of Common Stock in connection with any such conversion, any fractional share of Common Stock shall be rounded up or down to the next whole number or zero, as applicable (with one-half being closer to the next lower whole number for this purpose).
  
  	 
	4
	

	 

 
  
 4.4 Adjustments for Stock Splits, Business Combinations, etc.
  
 (a) Stock Splits, Subdivisions, Reclassifications or Combinations. If the Corporation, (i) pays any dividends or distributions with respect to the Common Stock in the form of additional shares of Common Stock, or (ii) subdivides (by stock split, recapitalization or otherwise) the outstanding shares of Common Stock into a greater number of shares, the number of shares of Common Stock issuable upon the Automatic Conversion or an Optional Conversion shall be proportionately increased. If the Corporation combines (by reverse stock split, recapitalization or otherwise) the outstanding Common Stock into a smaller number of shares, the number of shares of Common Stock issuable upon the Automatic Conversion or an Optional Conversion shall be proportionately decreased. Any adjustment under this Section 4.4(a) hereof shall become effective at 5:00 p.m. Eastern Time on the date the dividend, subdivision or combination becomes effective, and successive adjustments shall be made whenever any such dividend, subdivision or combination occurs.
  
 (b) Business Combinations. In the event of any (i) reorganization, consolidation, merger, share exchange or similar business combination transaction involving the Corporation with any third party, or (ii) any sale, assignment, conveyance, transfer, lease or other disposition by the Corporation or any of its subsidiaries to a third party of all or substantially all of the Corporation's assets, or assets constituting all or substantially all of the assets of the Corporation and its subsidiaries on a consolidated basis (a “Business Combination”), lawful provision shall be made as part of the terms of such Business Combination whereby each Series G Holder shall have the right thereafter to convert each share of Series G Preferred Stock held by such Series G Holder only into the kind and amount of securities, cash and other property receivable upon the Business Combination by a holder of the number of shares of Common Stock that a Series G Holder of a share of Series G Preferred Stock would have received assuming such share was converted pursuant to an Optional Conversion immediately prior to such Business Combination. The Corporation or the Person formed by the consolidation or resulting from the merger or which acquires such assets or which acquires the shares of the Corporation's capital stock, as the case may be, shall make provisions in its certificate or articles of incorporation or other constituent documents (each, a “Constituent Document”) to establish such rights and to ensure that the dividend, voting, conversion and other rights of the Series G Holders established herein are unchanged. Such Constituent Documents or any amendment thereof in accordance with this Section 4.4(b) shall contain terms as nearly equivalent as may be practicable to the terms provided for in this resolution, including adjustments, which, for events subsequent to the effective date of such Constituent Documents, shall be as nearly equivalent as may be practicable to the adjustments provided for in this Section 4.4(b).
  
 (c) Other Adjustments. If any transaction or event of the type contemplated by 4.4(a) or Section 4.4(b) hereof but not explicitly provided for in this Section 4.4 occurs with respect to the Common Stock, the Board of Directors shall take appropriate action as may be necessary or appropriate as determined in its reasonable good faith judgment to protect the rights of the Series G Holders of shares of Series G Preferred Stock in a manner consistent with the provisions of this Section 4.4.
  
 (d) Statement Regarding Adjustments. Promptly following any adjustment to the number of shares of Common Stock issuable upon an Automatic Conversion or an Optional Conversion as provided in Section 4.4(a) hereof or any other adjustment as provided in Section 4.4(b) or Section 4.4(c) hereof, the Corporation shall:
  
 (i) file, at the principal office of the Corporation, a statement showing in reasonable detail the facts requiring such adjustment, and, as applicable, the number of shares of Common Stock that would be issuable if an Automatic Conversion took place immediately after such adjustment; and
  
 (ii) promptly deliver a copy of such statement to each Series G Holder.
  
  	 
	5
	

	 

 
  
 5. Protective Provisions. While shares of Series G Preferred Stock are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following without the without the unanimous written consent or unanimous affirmative vote of the Series G Holders, voting separately as a single class (in addition to any other vote required by law or the Certificate of Incorporation), and any such act or transaction entered into without such consent or vote shall be null and void ab initio, and of no force or effect:
  
 (a) alter or change the rights, preferences or privileges of the Series G Preferred Stock;
  
 (b) alter or change the rights, preferences or privileges of any capital stock of the Corporation so as to affect adversely the Series G Preferred Stock;
  
 (c) amend, alter or repeal any provision of the Certificate of Incorporation or Bylaws in a manner that adversely affects the powers, preferences or rights of the Series G Preferred Stock;
  
 (d) enter into any agreement, commitment, understanding or other arrangement to take any of the foregoing actions, or cause or authorize any subsidiary of the Corporation to engage in any of the foregoing actions; or
  
 (e) take any other action which is required to be taken only with the consent or approval of the holders of the Corporation’s capital stock, whether pursuant to the Certificate of Incorporation, the Bylaws or the provisions of the DGCL.
  
 6. Notices. Any notice required or permitted by the provisions of this resolution to be given to a Series G Holder shall be mailed, postage prepaid, to the mailing address for such Series G Holder last shown on the records of the Corporation, or given by electronic communication in compliance with the provisions of the DGCL, and shall be deemed sent upon such mailing or electronic transmission.
  
 7. No Redemption. The shares of Series G Preferred Stock shall not be redeemable by the Corporation.
  
 8. Rank. Unless otherwise provided in the Certificate of Incorporation or a certificate of designation relating to a subsequent series of preferred stock of the Corporation, the Series G Preferred Stock shall rank junior to all other series of the Preferred Stock as to the payment of dividends and the distribution of assets on liquidation, dissolution or winding-up, and on a parity with the Common Stock.
  
 9. Fractional Shares. Series G Preferred Stock may be issued in fractions of a share (in one one-hundredths (1/100th) of a share and integral multiples thereof) which shall entitle a Series G Holder, in proportion to such Series G Holder’s fractional shares, to exercise voting rights, receive dividends, participate in distributions and to have the benefit of all other rights of Series G Holders.
  
  	 
	6
	

	 

 
  
 10. Waiver. Notwithstanding any provision in this resolution to the contrary, any provision contained herein and any right of the Series G Holders granted hereunder may be waived as to all shares of Series G Preferred Stock (and the Series G Holders thereof) only by the unanimous written consent or unanimous affirmative vote of the Series G Holders, voting separately as a single class.
  
 11. Severability. Whenever possible, each provision hereof shall be interpreted in a manner as to be effective and valid under applicable law, but if any provision hereof is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating or otherwise adversely affecting the remaining provisions hereof. If a court of competent jurisdiction determines that a provision hereof would be valid or enforceable if a period of time were extended or shortened or a particular percentage were increased or decreased, then such court may make such change as shall be necessary to render the provision in question effective and valid under applicable law.
  
 12. Lost or Mutilated Preferred Stock Certificate. Upon receipt of evidence reasonably satisfactory to the Corporation of the ownership and the loss, theft, destruction or mutilation of any certificate evidencing shares of Series G Preferred Stock, and in the case of any such loss, theft or destruction upon receipt of indemnity reasonably satisfactory to the Corporation or in the case of any such mutilation upon surrender of such certificate, the Corporation shall, at its expense, execute and deliver in lieu of such certificate a new certificate of like kind representing the number of shares of such class represented by such lost, stolen, destroyed or mutilated certificate and dated the date of such lost, stolen, destroyed or mutilated certificate.
  
 13. Headings. The headings contained herein are for convenience only, do not constitute a part of this resolution and shall not be deemed to limit or affect any of the provisions hereof.
  
 IN WITNESS WHEREOF, the Corporation has caused this resolution to be signed by Jon N Leonard, its Secretary, this 23rd Day of November, 2022.
  
  
  	  
	 TAUTACHROME INC.
	  

	  
	  
	  

		 /s/ Jon N Leonard
	  

	  
	 Name: Jon N Leonard
	  

	  
	 Title: Secretary
	  

 
  
  	 
	7
	

	 

 
  
 ANNEX I
  
 TAUTACHROME INC.
 SERIES G PREFERRED STOCK
  
 CONVERSION NOTICE
  
 The undersigned hereby irrevocably elects to convert __________________________________ shares of Series G Preferred Stock (the “Conversion”), represented by Stock Certificate No(s)._______________________ (the “Series G Certificates”), into shares of common stock (“Common Stock”) of Tautachrome Inc. (the “Corporation”) according to the conditions of the Certificate of Designations, Preferences, Rights and Limitations of Series G Preferred Stock, as of the date written below. If securities are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. No fee will be charged to the holder for any conversion, except for transfer taxes, if any. Each Series G Certificate is attached hereto (or evidence of loss, theft or destruction thereof).
  
 In the event of partial exercise, please reissue a new stock certificate for the number of shares of Series G Preferred Stock that are not converted.
  
 The undersigned acknowledges and agrees that all offers and sales by the undersigned of the securities issuable to the undersigned upon conversion of the Series G Preferred Stock have been or will be made only pursuant to an effective registration of the transfer of the Common Stock under the Securities Act of 1933, as amended (the “Act”), or pursuant to an exemption from registration under the Act.
  
 Date of Conversion:                                                    
  
 Signature:                                                                    
  
 Name:                                                                          
  
 Address:                                                                                  
  
  	 
	8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]